Loading...
XHKG
1952
Market cap1.83bUSD
May 30, Last price  
44.15HKD
1D
0.80%
1Q
-5.66%
IPO
-42.77%
Name

Everest Medicines Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
18.63
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.50%
Rev. gr., 5y
%
Revenues
707m
+461.16%
00054,00012,792,000125,932,000706,678,000
Net income
-1.04b
L+23.32%
-991,674,000-193,472,000-5,681,985,000-1,013,535,000-247,283,000-844,463,000-1,041,375,000
CFO
-680m
L-11.66%
-106,967,000-88,657,000-471,899,000-729,936,000-1,155,761,000-769,190,000-679,513,000

Profile

Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
URL
https://www.everestmedicines.com/
IPO date
Oct 09, 2020
Employees
395
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
706,678
461.16%
125,932
884.46%
12,792
23,588.89%
Cost of revenue
1,463,970
971,042
1,417,615
Unusual Expense (Income)
NOPBT
(757,292)
(845,110)
(1,404,823)
NOPBT Margin
Operating Taxes
8
Tax Rate
NOPAT
(757,292)
(845,110)
(1,404,831)
Net income
(1,041,375)
23.32%
(844,463)
241.50%
(247,283)
-75.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
29,787
5,281
BB yield
-0.46%
-0.10%
Debt
Debt current
488,989
41,316
444,408
Long-term debt
136,165
527,958
138,941
Deferred revenue
6,053
Other long-term liabilities
5,898
28,614
30,923
Net debt
(1,007,859)
(1,829,347)
3,319
Cash flow
Cash from operating activities
(679,513)
(769,190)
(1,155,761)
CAPEX
(65,406)
(117,336)
(432,743)
Cash from investing activities
974,396
752,497
(1,028,025)
Cash from financing activities
37,800
10,103
(25,311)
FCF
(831,125)
498,569
(3,178,702)
Balance
Cash
1,603,308
2,349,691
1,651,376
Long term investments
29,705
48,930
(1,071,346)
Excess cash
1,597,679
2,392,324
579,390
Stockholders' equity
4,072,794
(9,016,262)
5,654,486
Invested Capital
3,056,619
14,530,223
5,603,769
ROIC
ROCE
EV
Common stock shares outstanding
320,918
313,063
297,635
Price
48.40
131.58%
20.90
20.25%
17.38
-46.69%
Market cap
15,532,412
137.39%
6,543,013
26.49%
5,172,896
-45.89%
EV
14,524,553
4,713,666
5,176,215
EBITDA
(623,674)
(768,334)
(1,362,051)
EV/EBITDA
Interest
23,059
5,591
Interest/NOPBT